<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>E药经理人 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-12-11T20:30:19+08:00</updated>
  <subtitle>我们致力于成为医药行业意见领袖平台，我们记录和观察医药重大商业事件，展现这个行业的复杂和冲突，提供最前线的思想火花。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>恒瑞第七款创新药获批在即，直面百济、再鼎与AZ！进击全球TOP15！</title>
    <updated>2020-12-11T17:35:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/G-mwe2waksBbmg7HuUeWkw</id>
    <link href="https://mp.weixin.qq.com/s/G-mwe2waksBbmg7HuUeWkw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>日本媒体眼中的中国集采和“败”下阵来的卫材、参天、科研</title>
    <updated>2020-12-11T17:35:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/V6m1Bwx1dJZLcWBg0N3T5Q</id>
    <link href="https://mp.weixin.qq.com/s/V6m1Bwx1dJZLcWBg0N3T5Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>医保局考虑把更多罕见病用药纳入集采，涉及杨森、诺和诺德等数十亿美元品种！</title>
    <updated>2020-12-11T17:35:46+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-11:/s/QwOKNbk4QTd0yx9pZQTCeA</id>
    <link href="https://mp.weixin.qq.com/s/QwOKNbk4QTd0yx9pZQTCeA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>研发30年，致敬诺奖级肿瘤疗法！</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/-JcW3DGzwwNFEvYayt3W4w</id>
    <link href="https://mp.weixin.qq.com/s/-JcW3DGzwwNFEvYayt3W4w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第四批集采：44品种，谁竞争最激烈？谁价格最低？谁市场最大？谁最波折？替格瑞洛为何二次进集采？</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/9yH2QXT9ln8Ie5eBB0ftUQ</id>
    <link href="https://mp.weixin.qq.com/s/9yH2QXT9ln8Ie5eBB0ftUQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>你会接种新冠疫苗吗？辉瑞疫苗存隐患，志愿者接种后出现副作用。</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/h6Jj_2A4aLLCldT_hPx3qw</id>
    <link href="https://mp.weixin.qq.com/s/h6Jj_2A4aLLCldT_hPx3qw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>智慧医疗投资，赢在何方？挑战是什么？</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/7EyWVoiCiH4SngV0bLjjYw</id>
    <link href="https://mp.weixin.qq.com/s/7EyWVoiCiH4SngV0bLjjYw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>投资人视角|提高直接融资比重，强化资本市场功能</title>
    <updated>2020-12-10T21:38:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-10:/s/irAwosrB0FZgZi8FqL704w</id>
    <link href="https://mp.weixin.qq.com/s/irAwosrB0FZgZi8FqL704w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>众多十亿美元级品种入选四批集采，这些药企涉及产品最多！这几个热门品种却没纳入！</title>
    <updated>2020-12-09T17:48:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/fB7l4_Et5g4IefNsUHsx7w</id>
    <link href="https://mp.weixin.qq.com/s/fB7l4_Et5g4IefNsUHsx7w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球问世30年，这项革命性分子互作技术为什么能成为行业金标准？</title>
    <updated>2020-12-09T17:48:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/6YnxY3BkvHov-bfIXa9-6w</id>
    <link href="https://mp.weixin.qq.com/s/6YnxY3BkvHov-bfIXa9-6w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首个用于治疗系统性红斑狼疮的靶向生物制剂贝利尤单抗获批儿童适应症，惠及五岁及以上患儿</title>
    <updated>2020-12-09T17:48:19+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-09:/s/Hlx9sAG5U5QQ3UkTjIqoGQ</id>
    <link href="https://mp.weixin.qq.com/s/Hlx9sAG5U5QQ3UkTjIqoGQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>独家专访复宏汉霖CEO张文杰：复宏汉霖进入发展第二阶段，要实现生物类似药和创新药双领导地位</title>
    <updated>2020-12-08T20:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/91guZL-GiHUE7zFCwpwIKQ</id>
    <link href="https://mp.weixin.qq.com/s/91guZL-GiHUE7zFCwpwIKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>他说：一般一年两次集采！500个品种动态调整，量大、竞争激烈优先纳入？</title>
    <updated>2020-12-08T20:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/9AkvXPoAE6oJCAdiD3y7_Q</id>
    <link href="https://mp.weixin.qq.com/s/9AkvXPoAE6oJCAdiD3y7_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅！恒瑞医药卡瑞利珠单抗+苹果酸法米替尼联合疗法被纳入拟突破性治疗品种公示</title>
    <updated>2020-12-08T20:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/o9EAbcKqdKVwEOfSr93cyg</id>
    <link href="https://mp.weixin.qq.com/s/o9EAbcKqdKVwEOfSr93cyg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>【投资人观点】京东健康首日市值超阿里健康，怎么看医药电商估值的高与低？</title>
    <updated>2020-12-08T20:09:00+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-08:/s/feF_tI41Ilj9zs724e6vew</id>
    <link href="https://mp.weixin.qq.com/s/feF_tI41Ilj9zs724e6vew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>30年医药产业资本浮沉，沃森生物有点“嫩”！</title>
    <updated>2020-12-07T21:20:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/z5GRaIwkLCzDQ_UDvRTzmA</id>
    <link href="https://mp.weixin.qq.com/s/z5GRaIwkLCzDQ_UDvRTzmA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>被高瓴称为“新冠疫苗黑马”，年产量可达10亿剂，获超20亿元国际资助，这家创新药企凭什么？</title>
    <updated>2020-12-07T21:20:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/GW43Qfz9ChBIhmfNnKsLFg</id>
    <link href="https://mp.weixin.qq.com/s/GW43Qfz9ChBIhmfNnKsLFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Ⅱ期临床成功率被提升2倍！辉瑞如何做到的？</title>
    <updated>2020-12-07T21:20:44+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-07:/s/Pr1ddCAdgjJTH09PXqBtxA</id>
    <link href="https://mp.weixin.qq.com/s/Pr1ddCAdgjJTH09PXqBtxA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞员工评价孙飘扬：他真的是喜欢研发！</title>
    <updated>2020-12-06T18:34:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/-eNf6L-57mzQUUILWAEDdA</id>
    <link href="https://mp.weixin.qq.com/s/-eNf6L-57mzQUUILWAEDdA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>不选择license in，看璎黎药业的从0到1之路</title>
    <updated>2020-12-06T18:34:39+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-12-06:/s/Fq44bY_k3C2rRpEM5fXHxQ</id>
    <link href="https://mp.weixin.qq.com/s/Fq44bY_k3C2rRpEM5fXHxQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>